Reuters Market Eye - Sun Pharmaceutical Industries
If the offer is fully subscribed, the number of Taro shares to be purchased in the offer represents approximately 4.6 to 5.3 percent of the unit's total outstanding shares.
Sun Pharma's stake in Taro will go up to more than 69 percent from 66 percent should the buyback be fully subscribed.
(Reporting by Abhishek Vishnoi)